SCHEMBL3083932

SCHEMBL3083932

CCN(CC)C(=O)C(Cc1ccc(NC(=O)c2c(C)cccc2C)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
F2 P00734 4/20 0.43
LARS1 Q9P2J5 1/20 0.43
KAT6A Q92794 3/20 0.40
ITGB1 P05556 2/20 0.40
ITGA4 P13612 2/20 0.40
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
PKM P14618 1/20 0.38
PKLR P30613 1/20 0.38
ITGA2 P17301 1/20 0.38
ITGB7 P26010 1/20 0.38
PLG P00747 1/20 0.38
AR P10275 1/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3093284 0.92 KAT6A (0.49) F2LARS1KAT6ANPC1RAB9A
SCHEMBL3100534 0.92 KDR (0.43) F2LARS1KAT6ANPC1RAB9A
SCHEMBL3079467 0.91 F2 (0.43) F2LARS1KAT6AITGB1ITGA4
SCHEMBL3091891 0.90 F2 (0.43) F2LARS1KAT6ANPC1RAB9A
SCHEMBL3088121 0.89 ALOX15 (0.43) F2LARS1KAT6ANPC1RAB9A
SCHEMBL3093901 0.89 MMP9 (0.46) F2LARS1KAT6ANPC1RAB9A
SCHEMBL3102970 0.89 MMP9 (0.46) F2LARS1KAT6ANPC1RAB9A
SCHEMBL3092720 0.88 MEN1 (0.53) F2LARS1KAT6ANPC1RAB9A
SCHEMBL3090792 0.88 NPC1 (0.51) F2LARS1KAT6ANPC1RAB9A
SCHEMBL3092998 0.88 NPC1 (0.51) F2LARS1KAT6ANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 F2 4128/4885LARS1 1976/4885KAT6A 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.